Vital Peptide Lab evaluates a claim, not a brand reputation. The unit of review is a sentence that can be checked: a named substance or service, a defined population, a formulation when it matters, a comparator, an outcome, a time horizon, and a source. A real paper can still be the wrong support if any of those elements drift.
The review record we build
| Step | Question | Recorded output |
|---|---|---|
| 1. Define | What exact claim is being made? | Substance or service, population, outcome, and timeframe. |
| 2. Match | Does the source test that claim? | Model, formulation, route, comparator, endpoint, and duration. |
| 3. Stress-test | What would weaken the inference? | Sample size, bias, missing safety data, conflicts, and indirectness. |
| 4. Classify | What can the evidence support? | Supported, partly supported, unsupported, or not assessable. |
| 5. Disclose | Could a commercial relationship affect presentation? | Relationship, placement, and editorial-separation note. |
This workflow is deliberately narrower than a rating. A rating can hide why a strong laboratory document does not establish clinical benefit, or why a licensed telehealth service still needs clear prescribing and follow-up information. The evidence record keeps those questions separate.
Different sources answer different questions
- Analytical report: may describe a specified test on an identified sample. It does not establish clinical effect, individualized safety, or consistency across untested batches. The ICH Q2(R2) guideline explains why an analytical procedure must be fit for its intended purpose.
- Cell or animal study: can test biological questions under controlled conditions. It does not by itself establish a human outcome.
- Human pharmacology study: can show exposure or a biomarker response in its participants. It may not test a patient-important benefit or long-term harm.
- Controlled clinical study: can support the population, comparator, endpoint, and duration actually studied. It does not automatically transfer to another product or indication.
- Label or agency document: can establish product-specific approval language or a regulator’s stated concern. It is not a universal judgment about every molecule with a similar name.
- Vendor or telehealth statement: can document what an organization says it offers. It is not independent evidence that the statement is correct.
Vendor documentation and telehealth accountability are separate tracks
For research vendors, we look for a traceable batch identifier, named methods, units, acceptance criteria, dates, and a clear relationship between the sample and the document. We do not convert identity, purity, or endotoxin results into a conclusion about medical suitability. FDA’s Q6A specifications guidance is a useful reminder that identity, assay, impurities, sterility, and endotoxin are distinct quality questions.
For telehealth programs, the audit concerns clinical accountability: who evaluates the patient, where the clinician is licensed, which pharmacy dispenses a prescribed product, what follow-up exists, how adverse events are handled, and whether privacy and cancellation terms are understandable. A polished vendor certificate cannot answer those service questions, and a licensed consultation cannot validate an unrelated research product.
How we handle commercial relationships
As of this revision, this article contains no vendor rating, affiliate link, coupon, or paid placement. If a commercial relationship is introduced, it must be disclosed near the affected content. The relationship does not buy a conclusion, remove a limitation, or convert a source into stronger evidence. We will not present a vendor-supplied document as independent verification.
Material factual errors are corrected when a clearer primary source, label, or agency document changes the record. A correction should identify what changed and why. New evidence is reviewed against the same claim definition rather than appended as a keyword match.
What a reader should be able to audit
A consequential conclusion should let the reader answer five questions: What exactly was studied? In whom or in what model? Compared with what? Which endpoint and duration? What remains unknown? If the article cannot make that chain visible, the conclusion should remain provisional.
Vital Peptide Lab is an educational publisher, not a laboratory, regulator, pharmacy, or clinical practice. That limitation is part of the method: we can inspect documents and reasoning, but we do not reproduce assays, authenticate every batch, or decide whether a treatment is appropriate for an individual.
